• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙硫氧嘧啶诱导的大鼠模型反映了临床上非肥胖非酒精性脂肪性肝病患者的异质性。

Propylthiouracil Induced Rat Model Reflects Heterogeneity Observed in Clinically Non-Obese Subjects with Nonalcoholic Fatty Liver Disease.

机构信息

School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

School of Pharmacy, University of Wisconsin Madison, Madison, WI 53705, USA.

出版信息

Int J Mol Sci. 2024 Oct 7;25(19):10764. doi: 10.3390/ijms251910764.

DOI:10.3390/ijms251910764
PMID:39409093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11477315/
Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, affecting up to 30% of the population, with approximately 20% of cases occurring in non-obese individuals. The recent shift to the term metabolic dysfunction-associated steatosis liver disease (MASLD) highlights the disease's heterogeneity. However, there are no well-established animal models replicating non-obese NAFLD (NO-NAFLD). This study aimed to evaluate the relevance of the high-fat diet (HFD) combined with the propylthiouracil (PTU)-induced rat model in mimicking the histopathology and pathophysiology of NO-NAFLD. We first analyzed metabolic and clinical parameters between NO-NAFLD patients (Average BMI = 21.96 kg/m) and obese NAFLD patients (Average BMI = 29.7 kg/m). NO-NAFLD patients exhibited significantly higher levels of carnitines, phospholipids, and triglycerides. In the animal model, we examined serum lipid profiles, liver inflammation, histology, and transcriptomics. Hepatic steatosis in the HFD+PTU model at week 4 was comparable to that of the HFD model at week 8. The HFD+PTU model showed higher levels of carnitines, phospholipids, and triglycerides, supporting its relevance for NO-NAFLD. Additionally, the downregulation of lipid synthesis-related genes indicated differences in lipid accumulation between the two models. Overall, the HFD+PTU-induced rat model is a promising tool for studying the molecular mechanisms of NO-NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)的患病率正在上升,影响多达 30%的人群,其中约 20%的病例发生在非肥胖个体中。最近术语改为代谢功能障碍相关脂肪性肝病(MASLD),突出了该疾病的异质性。然而,目前还没有能够复制非肥胖性非酒精性脂肪性肝病(NO-NAFLD)的成熟动物模型。本研究旨在评估高脂肪饮食(HFD)联合丙硫氧嘧啶(PTU)诱导的大鼠模型在模拟 NO-NAFLD 的组织病理学和发病机制方面的相关性。我们首先分析了 NO-NAFLD 患者(平均 BMI = 21.96 kg/m)和肥胖性 NAFLD 患者(平均 BMI = 29.7 kg/m)之间的代谢和临床参数。NO-NAFLD 患者的肉碱、磷脂和甘油三酯水平显著升高。在动物模型中,我们检测了血清脂质谱、肝脏炎症、组织学和转录组学。HFD+PTU 模型在第 4 周的肝脂肪变性与 HFD 模型在第 8 周的肝脂肪变性相当。HFD+PTU 模型显示出更高水平的肉碱、磷脂和甘油三酯,支持其与 NO-NAFLD 的相关性。此外,脂质合成相关基因的下调表明两种模型之间脂质积累的差异。总的来说,HFD+PTU 诱导的大鼠模型是研究 NO-NAFLD 分子机制的有前途的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/e6f4fbe81552/ijms-25-10764-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/d750b98e32cd/ijms-25-10764-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/1a4e3d2dc51b/ijms-25-10764-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/9ab1e54feb7c/ijms-25-10764-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/e6f4fbe81552/ijms-25-10764-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/d750b98e32cd/ijms-25-10764-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/1a4e3d2dc51b/ijms-25-10764-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/9ab1e54feb7c/ijms-25-10764-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd14/11477315/e6f4fbe81552/ijms-25-10764-g004.jpg

相似文献

1
Propylthiouracil Induced Rat Model Reflects Heterogeneity Observed in Clinically Non-Obese Subjects with Nonalcoholic Fatty Liver Disease.丙硫氧嘧啶诱导的大鼠模型反映了临床上非肥胖非酒精性脂肪性肝病患者的异质性。
Int J Mol Sci. 2024 Oct 7;25(19):10764. doi: 10.3390/ijms251910764.
2
The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).β3 肾上腺素能受体激动剂 BRL37344 对高脂肪饮食诱导的非酒精性脂肪性肝病(NAFLD)大鼠模型肝脂肪变性和炎症的保护作用。
Mol Med. 2020 Jun 5;26(1):54. doi: 10.1186/s10020-020-00164-4.
3
Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats.在高脂饮食诱导的肥胖大鼠中,与非酒精性肝损伤进展相关的是游离脂肪酸,而非甘油三酯。
Lipids Health Dis. 2016 Feb 11;15:27. doi: 10.1186/s12944-016-0194-7.
4
Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD.肝 CPT1A 基因治疗可减少小鼠饮食诱导的肝脂肪变性,并突出了人类非酒精性脂肪性肝病的潜在脂质生物标志物。
FASEB J. 2020 Sep;34(9):11816-11837. doi: 10.1096/fj.202000678R. Epub 2020 Jul 15.
5
Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.长期皮下注射脂多糖和高脂肪饮食通过 IKKε/NF-κB 信号诱导非酒精性脂肪性肝病。
Biochem Biophys Res Commun. 2020 Nov 12;532(3):362-369. doi: 10.1016/j.bbrc.2020.08.036. Epub 2020 Aug 31.
6
Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.小檗碱通过激活 SIRT3/AMPK/ACC 通路改善高脂饮食诱导的大鼠非酒精性脂肪肝病。
Curr Med Sci. 2019 Feb;39(1):37-43. doi: 10.1007/s11596-019-1997-3. Epub 2019 Mar 13.
7
1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.1,2,3,4,6-五没食子酰基-β-D-葡萄糖可改善高脂饮食诱导的非酒精性脂肪肝病,并维持参与脂类动态平衡的基因在小鼠体内的表达。
Biomed Pharmacother. 2020 Sep;129:110348. doi: 10.1016/j.biopha.2020.110348. Epub 2020 Jun 15.
8
Niacin increases diet-induced hepatic steatosis in B6129 mice.烟酸会增加 B6129 小鼠饮食诱导的肝脂肪变性。
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Sep;1865(9):158731. doi: 10.1016/j.bbalip.2020.158731. Epub 2020 May 11.
9
Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: The alleviating effect and its mechanism of Polygonatum kingianum.高脂饮食诱导的非酒精性脂肪肝疾病中线粒体功能障碍:黄精的缓解作用及其机制。
Biomed Pharmacother. 2019 Sep;117:109083. doi: 10.1016/j.biopha.2019.109083. Epub 2019 Jul 4.
10
Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats.绿茶多酚通过上调高脂喂养的 Zucker 肥胖大鼠的 AMPK 激活来改善非酒精性脂肪性肝病。
World J Gastroenterol. 2017 Jun 7;23(21):3805-3814. doi: 10.3748/wjg.v23.i21.3805.

本文引用的文献

1
Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification.代谢组学在临床生物标志物发现和治疗靶点鉴定中的应用。
Molecules. 2024 May 8;29(10):2198. doi: 10.3390/molecules29102198.
2
Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis.非酒精性脂肪肝和全因死亡率的关系:一项更新的荟萃分析。
Ann Hepatol. 2024 May-Jun;29(3):101288. doi: 10.1016/j.aohep.2024.101288. Epub 2024 Jan 24.
3
Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease.
瘦型非酒精性脂肪性肝病的临床特征和蛋白质组学特征。
Front Endocrinol (Lausanne). 2023 Nov 16;14:1171397. doi: 10.3389/fendo.2023.1171397. eCollection 2023.
4
Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis.非酒精性脂肪性肝病消瘦人群中的胃肠道癌症:系统评价和荟萃分析。
Liver Int. 2024 Jan;44(1):6-14. doi: 10.1111/liv.15763. Epub 2023 Oct 13.
5
Epidemiology of lean/non-obese nonalcoholic fatty liver disease in China: A systematic review and meta-analysis.中国非肥胖/非酒精性脂肪性肝病的流行病学:系统评价和荟萃分析。
Saudi Med J. 2023 Sep;44(9):848-863. doi: 10.15537/smj.2023.44.9.20230021.
6
Assessing the Influence of Propylthiouracil and Phenytoin on the Metabolomes of the Thyroid, Liver, and Plasma in Rats.评估丙硫氧嘧啶和苯妥英对大鼠甲状腺、肝脏和血浆代谢组的影响。
Metabolites. 2023 Jul 14;13(7):847. doi: 10.3390/metabo13070847.
7
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
8
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.全球非酒精性脂肪性肝病发病率:63 项研究和 1,201,807 人的系统评价和荟萃分析。
J Hepatol. 2023 Aug;79(2):287-295. doi: 10.1016/j.jhep.2023.03.040. Epub 2023 Apr 9.
9
The identification of metabolites from gut microbiota in NAFLD via network pharmacology.通过网络药理学鉴定非酒精性脂肪性肝病肠道微生物群中的代谢物。
Sci Rep. 2023 Jan 13;13(1):724. doi: 10.1038/s41598-023-27885-w.
10
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.